Background: High body mass index (BMI) is known to be associated with inadequate clinical response to anti-TNF agents in rheumatoid arthritis (RA) patients. 1 However, there are limited data on the effect of high BMI on the response to rituximab in RA patients, who showed an inadequate response or intolerance to anti-TNF agents. Objectives: To investigate the impact of BMI on clinical response in the post-hoc analysis of randomized controlled trial that demonstrated clinical equivalence between a biosimilar of rituximab, CT-P10 and innovator rituximab, RTX 2 (NCT02149121). Methods: A total of 332 patients who received two courses of either CT-P10 or RTX were included in this analysis. Patients were classified into 3 groups; normal weight (<25kg/m 2 ), overweight (≥25 kg/m 2 ∼<30 kg/m 2 ) and obesity (≥30 kg/m 2 ) as per WHO BMI category. Improvement in disease activity by the Disease Activity Score using C-reactive protein (DAS28-CRP), remission (≤2.6), low disease activity rate (LDA, ≤3.2) and ACR response at Week 24 (Week 24 of 1st course) and Week 48 (Week 24 of 2nd course) and duration of sustained LDA (from the first LDA observed to the last LDA observed up to Week 48) were analysed by BMI categories in the each and combined group of CT-P10 and RTX. Results: In the pooled group of CT-P10 and RTX, the mean weights were 59 kg in normal weight, 73kg in overweight and 91kg in obesity. All other baseline characteristics were comparable among BMI groups including baseline disease activity based on DAS28; Moderate disease activity, 22.3% vs. 22.8% vs. 25.7%, respectively; High disease activity, 77.7% vs. 77.2% vs. 74.3%, respectively. There was no statistical difference among BMI groups in terms of DAS28 change from baseline and ACR 20/50/70 response (Table) . No particular trend was observed in remission and LDA rate by DAS28 at Week 24 and Week 48 among BMI groups ( Figure) . Mean duration of sustained LDA (months) were also comparable Background: Women with active chronic rheumatic inflammatory conditions (RA, PsA, AxSpA) often face uncertainty regarding the safety of the use of biologics during breastfeeding.
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2 CRADLE (NCT02154425) was the first sponsored study to evaluate certolizumab pegol (CZP) concentrations in breast milk, and to estimate the Average Daily Infant Dose (ADID) of maternal CZP. Objectives: To determine the concentration of CZP in breast milk and calculate the ADID of maternal CZP. Methods: CRADLE was a pharmacokinetic study of lactating mothers (≥6 weeks postpartum) receiving commercial CZP. Decision to treat with CZP and breastfeed was independent of study participation. At steady state (≥3 CZP doses), breast milk samples were collected on Days 0, 2, 4, 6, 8, 10, 12, 14 (±28) from each mother across 1 dosing period. CZP was detected using a highly sensitive, CZP-specific electrochemiluminescence immunoassay validated in milk (lower limit of quantification [LLOQ]=0.032 μg/mL; 10-fold lower than previous assays). CZP stability in milk was confirmed. Results: 18 CZP-treated mothers were screened: 17 entered the sampling period; 16 on CZP 200 mg Q2W; 1 on CZP 400 mg Q4W (7 RA; 5 SpA; 5 CD; Table A) . Samples from 4/17 mothers had no measurable CZP in breast milk; 13/17 had quantifiable levels for at least 1 time point (highest concentration: 0.076 μg/mL; Table B ). Estimated ADID ranged 0-0.0104 mg/kg/day; median Relative Infant Dose (RID; calculated post hoc 3 ): 0.15%. Infants of CZP-exposed mothers had a safety profile consisting of events occurring in unexposed infants of similar age. Conclusions: CZP was below the lower limit of quantification in 56% of the milk samples. When detectable, CZP concentrations were less than 3x LLOQ (<1% of expected plasma concentration of a therapeutic dose 4 ), indicating no to minimal transfer of CZP from plasma to breast milk. RID was below 0.5% of maternal dose; <10% is unlikely to be of clinical concern.
3 CZP absorption via breast milk is unlikely, due to low bioavailability and its Fc-free molecular structure. These findings support continuation of CZP treatment during breastfeeding. 
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